Treatment of Carcinoid Syndrome

Initial Pharmacological Management

The National Comprehensive Cancer Network recommends somatostatin analogues, such as octreotide or lanreotide, as the first-line treatment for carcinoid syndrome, providing substantial relief of flushing and diarrhea in the majority of patients 1, 2
Start with octreotide short-acting formulation for initial stabilization before transitioning to long-acting preparations, with a dose of 50-100 mcg subcutaneously 2-3 times daily, titrating up to maximum 1500 mcg/day based on symptom control 3, 4
Stabilize patients for 10-28 days before converting to long-acting formulations 3, 4
Long-acting formulations, such as octreotide LAR or lanreotide, can be used for chronic management, with a standard starting dose of 20 mg intramuscularly every 4 weeks for octreotide LAR, and 60-120 mg deep subcutaneous injection monthly for lanreotide 1, 2

Patients undergoing anesthesia, surgery, or hepatic artery embolization require increased somatostatin analogue coverage, with short-acting octreotide administered at 50 mcg/hour intravenously starting 12 hours before, during, and 48 hours after procedures 3, 4

Obtain cardiology consultation and echocardiogram in patients with signs or symptoms of heart disease, planned major surgery, or high risk for carcinoid heart disease, defined as 5-HIAA levels ≥300 mcmol (57 mg) over 24 hours and ≥3 flushing episodes per day 1, 2, 5
Note that 59% of carcinoid syndrome patients have tricuspid regurgitation 1, 5

Telotristat ethyl can be used to reduce bowel movements in patients with SSA-refractory diarrhea, with a response rate of 40% 6
Peptide receptor radionuclide therapy (PRRT) can be effective for symptom control in functional NETs refractory to SSA, and may be considered in patients with high tumor burden and uncontrolled diarrhea even without prior progression (off-label) 6

Somatostatin analogues also control tumor growth, with a median time to progression of 14.3 months vs 6.0 months with placebo (p=0.000072) in the PROMID study, and a progression-free survival (PFS) not reached vs 18 months with placebo (HR 0.47, p<0.001) in the CLARINET study 1, 2

Regular assessment during treatment includes monitoring circulating and urinary hormone levels (5-HIAA, chromogranin A), performing regular imaging studies, and monitoring for side effects such as fat malabsorption, gallstones, vitamin A/D malabsorption, and glucose abnormalities 2, 3, 4